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Abstract To date, the genetic basis of Dubowitz syndrome
(short stature, microcephaly, facial abnormalities, eczema) is
unknown and vascular complications are not known to be
associated with this syndrome. In microcephalic osteodysplastic
primordial dwarfism type II (MOPD II; disproportionate short
statue, microcephaly, facial abnormalities), however, cerebral
aneurysms and other vascular abnormalities are frequent com-
plications. MOPD II is a genetic disorder caused by mutations
in the pericentrin (PCNT) gene (21q22). We report on a patient
who came to our attention as a 22-year-old with subarachnoid
bleeding due to a ruptured cranial aneurysm. Until then, the
patient was thought and published to have Dubowitz syndrome;
previously, he was treated with coronary bypass surgery for
extensive coronary angiopathy. Consecutive genetic testing
revealed MOPD II. After clinical stabilization, the patient was
discharged to a specialized rehabilitation center where he died
due to re-rupture of a cranial aneurysm. Conclusion: In patients
with short stature—especially when clinical features are accom-
panied by vascular complications—MOPD II should be con-
sidered as a differential diagnosis leading to consecutive genetic
testing. After detection of mutations in the PCNT gene, a full
vascular status including cerebral imaging and cardiac evalua-
tion needs to be determined in order to analyze vascular abnor-
malities and initiate prophylactic treatment.
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dwarfism type II
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Introduction
Microcephalic osteodysplastic primordial dwarfism type II
(MOPD II; OMIM: #210720) is one the most common types
of primordial dwarfism and is associated with high childhood
and juvenile mortality due to cerebral vessel anomalies, car-
diac problems, and early onset type 2 diabetes. As emphasized
in a review on pericentrin mutations and beyond by Rauch
2011, the shortest of the short individuals were found to have
MOPD II [5]. We report on a 22-year-old man with unexpect-
ed cerebral aneurysm bleeding finally diagnosed as MOPD II,
who was previously thought and published to have Dubowitz
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syndrome (OMIM: %223370) [7] delaying possible interven-
tional treatment.
Case report
The 22-year-old male patient presented with sudden onset of
severe headaches followed by a first tonic-clonic seizure.
Initial cranial computed tomography (CT) scan with CT angi-
ography revealed extensive intracranial hemorrhage (Fig. 1)
resulting from a ruptured aneurysm (size 9×6mm) of the right
proximal internal carotid artery that led to subarachnoid bleed-
ing (SAB). Furthermore, multiple cranial aneurysms (two
aneurysms of the right internal carotid artery, one aneurysm
of the head of the basilar artery, and one aneurysm of the left
posterior inferior cerebellar artery) as well as a moderate
narrowing of the left carotid artery were detected. The patient
was intubated, ventilated, and admitted to our pediatric inten-
sive care unit.
He had a previous history of myocardial infarction of the
anterior wall at the age of 17 years which was treated with
triple coronary bypass surgery. At that point, the patient was
thought to have Dubowitz syndrome which was suspected
because of the presence of the following clinical features:
apparent typical facial appearance, microcephaly, dwarfism
(last body weight 22 kg, last height 112 cm; there were no
measures available for head circumference, arm span and
lower and upper segments), and mild mental retardation [7].
Additionally, we found the patient to have a disproportionate-
ly short stature due to short limbs with truncal obesity, a poor
dentition status with small teeth of which some were missing
and with the remaining ones with mottled enamel and caries,
and a prominent nose. Also, intrauterine growth failure was
reported by the parents. He was known to have hypothyroid-
ism, systolic hypertension, hypertriglyceridemia, hypercho-
lesterolemia, and significantly reduced high-density lipopro-
tein cholesterol. A photograph of the patient was published by
Seeburger et al. [7]. In synopsis of all diagnostic findings, we
doubted the initial diagnosis of Dubowitz syndrome and con-
secutive genetic testing confirmed MOPD II. All of the clin-
ical findings in our patient except the hypothyroidism, the
lipid metabolism disorder, the history of myocardial infarc-
tion, and the systolic hypertension were consistent with this
diagnosis. Genetic testing revealed two compound heterozy-
gous mutations in the pericentrin (PCNT) gene inherited from
healthy carrier parents (c.1388C > G (exon 9) and c.5767C >
T (exon 28), both leading to a translational frameshift and
premature stop codons (p.S463* und p.R1923*)).
Following transfemoral endovascular coiling (right-sided
approach) of two aneurysms (Fig. 2, panels a and b), the
Fig. 1 Cranial computed tomographic scan on admission of the patient
showing right-sided subarachnoidal hemorrhage (left arrows) with blood
in the interhemispheric fissure (central arrows) and consecutive midline
shift to the left (white arrow)
Fig. 2 Cerebral aneurysms of the right internal carotid artery (shown in
panels a and b) occluded by multiple coils (arrows in b)
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clinical convalescence after SABwas prolonged and intensive
care treatment lasted as long as four weeks. The further
clinical course was complicated by generalized arterial
spasms, multiple thrombotic events, and long-term catechol-
amine therapy, all together leading to insufficient blood flow
in the right leg. Attempts of interventional as well as surgical
revascularization were unsuccessful; hence, right-sided
transgenicular leg amputation became necessary. Circulatory
deficiencies were also obvious in the remaining upper and
lower extremities, and furthermore, electrocardiogram (ECG)
showed recurrent ST-segment elevations with continuously
elevated blood levels of cardiac enzymes. Cardiac catheteri-
zation showed poor left ventricular function and a hypoplastic
coronary artery system (Fig. 3, panel a). Additionally, one of
the bypass grafts showed thrombotic occlusion and the other
one was found to be significantly obstructed (Fig. 3, panel b).
Mutations in theMTHFR gene were discovered (homozygous
for c.665C > T, heterozygous for c.1286A > C, OMIM:
*607093) partially explaining cardiovascular complications.
However, only limited treatment options were available and a
conservative approach administering partial thromboplastin
time (PTT)-controlled unfractionated heparin (PTT 40–50 s.)
was chosen. In the clinical course, the patient developed
pneumonia and broad-spectrum antibiotic treatment was re-
quired. Nevertheless, he became septic leading to cardiovas-
cular depression and ventricular fibrillation. Cardiopulmonary
resuscitation was effective with return of spontaneous circu-
lation after a few minutes.
Intracranial pressure was elevated for the first weeks after
SABmeasured continuously by Codman intracranial pressure
probe, so extraventricular drainage had to be established.
Later on, post hemorrhaging hydrocephalus aresorptivus be-
came evident and repeated predominantly right-sided seizures
occurred despite antiepileptic treatment with levetiracetam.
After one month of intensive medical care, the patient was
referred to a specialized rehabilitation center. At that time, he
still required invasive ventilation and had not adequately
regained consciousness after ending sedative measures.
Some weeks later, the patient died due to rupture of another
cerebral aneurysm.
Discussion
MOPD II is a genetic disorder caused by homozygous or
compound heterozygous mutations in the PCNT gene on
chromosome 21q22 [6]. Clinically, the syndrome was first
delineated byMajewski et al., who reported on three unrelated
children with intrauterine and postnatal dwarfism, facial fea-
tures resembling those of Seckel syndrome, and dispropor-
tionate shortness of forearms and legs [3]. In a review of 58
individuals withMOPD II, Hall et al. reported that 19% of the
patients were found to have intracranial aneurysms [2]. Other
vascular complications such as Moyamoya disease of the
cerebral arteries or tortuous cerebral vessels and cardiac prob-
lems altogether entailing life-threatening complications were
described as well [2, 5].
In our patient, the morphologic appearance in combination
with mild mental retardation had led to the diagnosis of
Dubowitz syndrome at a young age. Coronary artery
narrowing or other vascular complications had not been de-
scribed previously to be associated with this syndrome until
Seeburger et al. assumed to have found a new feature of
Dubowitz syndrome in the patient now diagnosed as having
MOPD II [7].
Dubowitz syndrome was first described in 1965 in four
patients with short stature, microcephaly, facial abnormalities,
mild mental retardation, and eczema [1]. So far, no causative
genetic abnormality is described. In a review of families with
two or more affected family members, Opitz et al. assumed an
autosomal recessive inheritance [4]. Vascular abnormalities
have not been described previously in this syndrome.
In our patient, it is highly probable that the development of
the cerebral aneurysms as well as of the coronary angiopathy
Fig. 3 Coronary angiography of
the left coronary artery showing
highly hypoplastic vessels
(arrows in a) and significant
narrowing of the venous
aortocoronary bypass to the
ramus circumflexus of the left
coronary artery with significant
distal stenosis (arrow in b)
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was a result of the vascular changes on the basis of the
mutation in the PCNT gene. It is likely that the cardiovascular
problems were aggravated by the presence of a homozygous
MTHFR mutation in this patient.
One can only speculate that earlier genetic testing and
earlier diagnosis of MOPD II would have led to earlier cranial
imaging and subsequently to preventive interventional treat-
ment of the cerebral aneurysms. It remains unclear if this had
improved the uncertain prognosis of this patient with severe
coronary artery disease. However, finding a pattern of symp-
toms not typical for a well known syndrome (in our case
Dubowitz syndrome) should always lead to reconsidering
genetically testable conditions. Whenever mutations in the
PCNT gene are detected in a patient with significant growth
retardation, a full vascular status including cerebral imaging
and cardiac evaluation needs to be determined as mortality is
high due to cerebrovascular anomalies.
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